866-997-4948(US-Canada Toll Free)

Synribo (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : May 2013

Category :

Oncology

No. of Pages : 50 Pages


Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

Tevas Synribo (omacetaxine mepesuccinate) is a chemotherapy for the treatment of CP or AP CML that is resistant to prior therapy with multiple TKIs. Synribo was originally developed by ChemGenex, which was bought by Cephalon in 2011, and is now a subsidiary of Teva. The MOA of Synribo has not been conclusively established; however, the drug has been shown to inhibit protein synthesis (Synribo Prescribing Information, 2012). Unlike its competitors, Synribo does not directly target BCR-ABL, although it did reduce in vitro levels of BCR-ABL and the anti-apoptotic proteins BCL-2 and MTL-1.

Scope


  • Overview of CML, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Synribo including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Synribo for the top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy


  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for CML
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Synribo performance
  • Obtain sales forecast for Synribo from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)
Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6

2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 7

3 Disease Overview 9
3.1 Etiology and Pathophysiology 9
3.1.1 Etiology 9
3.1.2 Pathophysiology 10
3.1.3 Clinical Staging 11
3.1.4 Prognosis 13
3.1.5 Quality of Life 14
3.2 Symptoms 15

4 Disease Management 16
4.1 Global Trends 16
4.1.1 Treatment Overview 16
4.1.2 Diagnostic Tests 19
4.1.3 Genetic Testing 20
4.1.4 Monitoring Patient Response to Treatment 22
4.1.5 Future Directions: Discontinuation Therapy 25

5 Competitive Assessment 27
5.1 Overview 27
5.2 Strategic Competitor Assessment 28

6 Product Profile - Synribo (omacetaxine mepesuccinate) 31
6.1 Overview 31
6.2 Efficacy 33
6.3 Safety 33
6.4 SWOT Analysis 34
6.5 Forecast 35

7 Appendix 36
7.1 Bibliography 36
7.2 Abbreviations 38
7.3 Methodology 41
7.4 Forecasting Methodology 41
7.4.1 Diagnosed CML patients 41
7.4.2 Drug-treated Patients on X Line of Therapy 42
7.4.3 General Pricing Assumptions 42
7.4.4 Individual Drug Assumptions 43
7.4.5 Generic Erosion 43
7.5 Physicians and Specialists Included in this Study 44
7.6 Survey of High Prescribing Physicians 45
7.7 About the Authors 46
7.7.1 Authors 46
7.7.2 Epidemiologists 47
7.7.3 Global Director of Epidemiology and Clinical Trials Analysis 48
7.7.4 Global Head of Healthcare 49
7.8 About GlobalData 50
7.9 Contact Us 50
7.10 Disclaimer 50

List of Table


Table 1: The Staging of CML as Defined by Commonly Used Staging Systems 12
Table 2: Prognostic Scoring Systems for CML 13
Table 3: Common Symptoms of CML by Disease Phase 15
Table 4: Most Commonly Followed Treatment Guidelines for CML 18
Table 5: Most Prescribed First-Line Therapies for CP, AP and BP CML in the Global Markets, 2013 18
Table 6: Suggested Treatments for CML Patients with Selected BCR-ABL Kinase Domain Mutations 21
Table 7: CML Response Types, Criteria, and Corresponding Tests 23
Table 8: Leading Treatments for Chronic Myeloid Leukemia, 2013 30
Table 9: Product Profile Synribo 32
Table 10: Synribo SWOT Analysis, 2013 34
Table 11: Global Sales Forecasts ($m) for Synribo in CML, 20122022 35
Table 12: Physicians Surveyed, by Country 45

List of Chart


Figure 1: Translocation of Chromosomes 9 and 22 9
Figure 2: Comparison of Normal and Leukemia Blood Cells 10

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *